Armistice Capital’s Cytokinetics CYTK Stock Holding History

Armistice Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$112M	Buy	1,700,000 +200,000	+13%	+$12.7M	1.99%	6
2025 Q4	$95.3M	Buy	1,500,000 +550,000	+58%	+$34.2M	1.13%	10
2025 Q3	$52.2M	Sell	950,000 -390,000	-29%	-$16.1M	0.77%	19
2025 Q2	$44.3M	Sell	1,340,000 -1,360,000	-50%	-$47.3M	0.76%	16
2025 Q1	$109M	Buy	2,700,000 +2,090,000	+343%	+$96M	1.63%	7
2024 Q4	$28.7M	Sell	610,000 -1,590,000	-72%	-$82.6M	0.39%	52
2024 Q3	$116M	Buy	2,200,000 +1,200,000	+120%	+$66.9M	1.86%	6
2024 Q2	$54.2M	Buy	1,000,000 +300,000	+43%	+$18.1M	0.68%	20
2024 Q1	$49.1M	Buy	+700,000	New	+$54.1M	0.65%	21

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's CYTK Position: Q1 2026 in Review

Armistice Capital reduced its Cytokinetics (CYTK) stake by 23% in Q1 2026, selling an estimated $14.5M and leaving 764,538 shares worth $50.4M. The position accounts for 0.9% of the portfolio, ranked #17.

Armistice Capital first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $112M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Armistice Capital held 764,538 shares of Cytokinetics worth $50.4M as of Q1 2026.
Armistice Capital sold 228,228 Cytokinetics shares in Q1 2026, an estimated $14.5M.
Cytokinetics made up 0.9% of Armistice Capital's portfolio in Q1 2026, its #17 holding.
Armistice Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
Armistice Capital's Cytokinetics position peaked at $112M in Q2 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.